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Abstract
Introduction: Recent large clinical trials have yielded disappointing results of
rosuvastatin in the chronic heart failure (CHF) population. The question that
remains is whether these results of rosuvastatin studies could be extended to
other statins. Therefore, we performed a meta-analysis based on all currently
available randomized controlled trials (RCTs) to evaluate the clinical efficacy of
atorvastatin in CHF patients.
Material and methods: The published literature was scanned by formal searches
of electronic databases up to January 2010. RCTs were eligible for inclusion if
they compared atorvastatin versus placebo treatment in patients with CHF and
reported the clinical outcomes. 
Results: Pre-specified criteria were met by 7 trials involving 540 patients. The
primary endpoint, all-cause mortality, was significantly reduced with atorvastatin
therapy compared with placebo in CHF patients (odds ratio [OR] 0.39, P = 0.002),
with similar results in cardiovascular mortality (OR 0.28, P = 0.002) and sudden
cardiac death (OR 0.24, P = 0.01). There was also a significant decrease in
hospitalization for worsening CHF with atorvastatin therapy compared with
placebo (OR 0.30, P < 0.001).
Conclusions: This meta-analysis suggests the effectiveness of atorvastatin
treatment in reducing the risks of all-cause mortality and worsening CHF
hospitalization in patients with CHF. Further large, well-conducted randomized
trials are needed to confirm the benefits of atorvastatin or other statins for CHF
relative to placebo or rosuvastatin.
Key words: statin, atorvastatin, heart failure
Introduction
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
(statins) reduce cardiovascular morbidity and mortality in patients with
coronary artery disease (CAD) (secondary prevention), and in individuals
at high risk of developing CAD (primary prevention) [1, 2]. However, the
potential benefits of different statins in patients with chronic heart failure
(CHF) remain controversial. Two recent large clinical trials have specifically
tested the effect of rosuvastatin in the CHF population, but both yielded
disappointing results [3, 4]. Whether these results of rosuvastatin studies
could be extended to the statin class or other statins is unclear. With
regards to atorvastatin, the results of several small randomized controlled
trials (RCTs) comparing it with placebo in patients with CHF have been
reported [5-19], but sample-size limitations in these studies prevented any
reliable conclusion. Meta-analysis has the potential to increase the power
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Therefore, we performed a meta-analysis based on
all currently available RCTs to evaluate the clinical
efficacy of atorvastatin in patients with CHF.
Material and methods
Data sources and selection criteria
To identify relevant trials, the electronic
databases (PubMed, EMBASE and the Cochrane
Central Register of Controlled Trials) were searched
using the following key words: randomized, statin,
hydroxymethylglutaryl-CoA reductase inhibitor,
atorvastatin, heart failure, cardiac dysfunction. In
addition, we scanned conference proceedings from
the American College of Cardiology, the American
Heart Association, and the European Society of
Cardiology. The search was restricted to articles
indexed as a clinical trial involving human subjects.
The last search was performed in January 2010.
To be selected for this meta-analysis, studies
comparing atorvastatin versus placebo treatment
in patients with CHF had to be randomized and
have their results reported or made available by 
the trial investigators. All studies meeting the
requirements, regardless of the language or form
of publication, were considered to be eligible for
this meta-analysis. When there were multiple
reports from the same trial, we used the most
complete and/or recently reported data.
Study outcomes and data abstraction
The primary end point was all-cause mortality.
Other clinical outcomes of interest included
cardiovascular mortality, sudden cardiac death and
worsening hospitalization for CHF. Two investigators
independently performed data abstraction. In addition
to pertinent data on the outcomes of interest, we
gathered information on trial names, first author, year
of publication, and number of patients enrolled.
Disagreements were resolved by consensus.
Statistical analysis
Data were managed according to the intention-
to-treat principle. Odds ratios (OR) with 95%
confidence intervals (CI) were calculated as
summary statistics. The pooled OR was calculated
with the Mantel-Haenszel method for fixed effects
and the DerSimonian and Laird method for random
effects [21, 22]. To assess heterogeneity across trials,
we used Cochran’s test and means of the I2 statistic
[23]. We assessed publication bias with respect to
the primary outcomes of interest using a funnel
plot as well as the adjusted rank correlation test
according to the method of Begg and Mazumdar
[24]. A sensitivity analysis was performed by
assessing the contribution of individual studies to
the summary effect estimate with respect to the
primary outcomes. This was done by excluding each
trial one at a time and computing meta-analysis
estimates for the remaining studies. Results were
considered significant at P  < 0.05. Statistical
analyses were performed with Stata software
version 9.0 (Stata Corp, College Station, USA).
Results
Of the 955 potentially relevant articles initially
screened, a total of 15 trials that randomly
compared atorvastatin therapy with placebo in
patients with CHF were initially identified [5-19].
Eight studies [5-12] were then excluded due to the
prospective crossover design or the lack of data on
clinical outcomes. Thus, a total of 7 RCTs were
finally included in this meta-analysis, involving 540
patients (296 in the atorvastatin group and 244
controls) [13-19]. The main characteristics of these
trials are displayed in Table I and the main baseline
characteristics of enrolled patients in individual
trials are shown in Table II.
The primary endpoint, all-cause mortality, was
reported in all 7 trials. As shown in Figure 1, there
was a significant decrease in all-cause mortality
with atorvastatin therapy compared with placebo
by the fixed-effect model (6.4% vs. 14.8%, OR 0.39,
95% CI 0.21-0.71, P  = 0.002). There was no
significant heterogeneity between trials (P = 0.58,
I2 = 0%). No evidence of publication bias with
respect to all-cause mortality was found using the
Begg funnel plot and rank correlation test (P = 1.0).
Omission of individual trials from the analysis did
not have any relevant influence on the overall
results.
Both cardiovascular mortality and sudden cardiac
death were reported in 5 trials. During the follow-
up period, the risks of cardiovascular mortality
(5.5% vs. 16.8%, OR 0.28, 95% CI 0.12-0.63, 
P = 0.002; P = 0.63, I2 = 0% for heterogeneity) and
sudden cardiac death (2.4% vs. 10.1%, OR 0.24, 
95% CI 0.08-0.71, P = 0.01; P = 0.75, I2 = 0% for
heterogeneity) in patients with atorvastatin therapy
were also significantly lower than those in the
controls by the fixed-effect model.
Hospitalization for worsening CHF was reported
in 6 trials. As shown in Figure 2, there was
a significant decrease in hospitalization for
worsening CHF with atorvastatin therapy compared
with placebo by the fixed-effect model (10.4% vs.
25.4%, OR 0.30, 95% CI 0.18-0.52, P < 0.001). There
was no significant heterogeneity between trials 
(P = 0.76, I2 = 0%).
Discussion
By pooling all currently available RCTs which
reported clinical effects of atorvastatin in patients
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atorvastatin was associated with significantly
decreased risks of all-cause mortality, cardiovascular
mortality, sudden cardiac death and hospitalization
for worsening CHF, as compared with placebo.
Statins are widely known as therapeutic agents
for hypercholesterolaemia. Recently, evidence of
their pleiotropic effects, meaning outside of the
ability to reduce cholesterol levels, has emerged.
The potent pleiotropic effects of statins, including
potential benefits for myocardial cellular function,
down-regulation of tissue renin-angiotensin-
aldosterone system activation, restoration of
autonomic function, neoangiogenesis, and inhibition
of proinflammatory cytokines, could favourably
influence the natural history of CHF [25-30]. Statins
possess anti-inflammatory effects and decrease
vascular cell adhesion molecule-1 levels in CHF.31
Additionally, circulating lipids have the capacity to
detoxify bacterial lipopolysaccharides, which
stimulate the release of inflammatory cytokines in
CHF [32]. Taken together, the rationale supporting
the potential benefits of statin therapy in CHF is
well grounded [33, 34].
The first indirect information about the beneficial
effects of statins in CHF came from the post hoc
analyses of a landmark clinical trial of statin therapy.
In the Scandinavian Simvastatin Survival Study (4S)
[35], patients who had known CAD and
hypercholesterolaemia were included. A lower
incidence of symptomatic CHF was observed in the
simvastatin group, compared with the placebo
group. Also, there was a 19% relative risk reduction
in 5-year mortality with statin therapy in patients
who had CHF. Additionally, the Long-Term
Intervention with Pravastatin in Ischaemic Disease
(LIPID) [36] trial observed a mortality benefit of
pravastatin in CHF (P < 0.05), while the Heart
Protection Study (HPS) [37] showed a marginal
reduction in mortality (3.4% in simvastatin vs. 3.9%
in placebo group) and hospitalization. The A to
Z trial [38] showed reduction of new-onset CHF by
18% (P < 0.05).
Recently, data from large observational studies
were consistent in showing a beneficial effect of
statins in patients with CHF [39-44]. The
retrospective trial by Foody et al. [39] evaluated
statin therapy in patients admitted to acute care
hospitals with a principal diagnosis of CHF. A sample
of 54 960 patients, all more than 65 years of age,
was analysed. Patients who received statins on
discharge (16.7%) were shown to have significant
reductions in 1-year mortality by 20% (P < 0.001)
and 3-year mortality by 18% (P < 0.001), even after
adjustment for clinical confounders. However, these
patients also had higher rates of cardiac
investigations, were more likely to be seen by
a cardiologist and received a higher rate of
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Arch Med Sci 6, December / 2010 869Study Atorvastatin (n/N)P lacebo (n/N)O dds Ratio Odds Ratio (95% CI)
Hamaad A, et al. 0/13 0/10
Sola S, et al. 4/54 4/54 1.00 (0.24, 4.22)
Wojnicz R, et al. 0/36 0/38
Yamada T, et al. 0/19 4/19 0.09 (0.004, 1.77)
Vrtovec B, et al. 9/55 20/55 0.34 (0.14, 0.84)
Xie RQ, et al. 5/78 7/41 0.33 (0.10, 1.12)
Bielecka-Dabrowa A, et al. 1/41 1/27 0.65 (0.04, 10.9)
Overall 19/296 36/244
Fixed effects 0.39 (0.21, 0.71)
Random effects 0.40 (0.22, 0.75)
Test for heterogeneity: chi-squared = 2.86 (d.f. = 4), P = 0.582
Test for overall effect: z = 3.08, P = 0.002 (fixed effects)
0.01 1 100
Favor atrovastatin Favor placebo
Figure 1. Odds ratios of all-cause mortality associated with atorvastatin versus placebo from individual studies and
overall population. The size of the data markers (squares) is approximately proportional to the statistical weight of
each trial
Study Atorvastatin (n/N)P lacebo (n/N)O dds Ratio Odds Ratio (95% CI)
Hamaad A, et al. 0/13 1/10 0.23 (0.01, 6.40)
Sola S, et al. 8/54 13/54 0.55 (0.21, 1.46)
Wojnicz R, et al. 0/36 2/38 0.20 (0.01, 4.31)
Yamada T, et al. 2/19 6/19 0.25 (0.04, 1.48)
Vrtovec B, et al. Data not available
Xie RQ, et al. 10/78 18/41 0.19 (0.08, 0.47)
Bielecka-Dabrowa A, et al. 5/41 8/27 0.33 (0.09, 1.15)
Overall 25/241 48/189
Fixed Effects 0.30 (0.18, 0.52)
Random Effects 0.30 (0.18, 0.52)
Test for heterogeneity: chi-squared = 2.64 (d.f. = 5), P = 0.756
Test for overall effect: z = 4.37, P < 0.001 (fixed effects)
0.01 1 100
Favor atrovastatin Favor placebo
Figure 2. Odds ratios of hospitalization for worsening chronic heart failure associated with atorvastatin versus placebo
from individual studies and overall population. The size of the data markers (squares) is approximately proportional
to the statistical weight of each trial
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870 Arch Med Sci 6, December / 2010concomitant aspirin, beta-blockers and angiotensin-
converting enzyme inhibitor prescriptions on
discharge. Another large observational cohort study
by Go et al. [40] involved 24 598 adults diagnosed
with CHF who had no prior statin use. Using an
intent-to-treat approach, incident statin use was
associated with a 21% (P < 0.001) and 24% 
(P < 0.001) reduction in hospitalization for CHF and
total mortality, respectively. It is important to note
that statins were more likely to be prescribed in
younger patients and those known to have CAD,
diabetes, or hypertension in this study. A pre-
specified post hoc analysis of the TNT trial (80 vs.
10 mg/d atorvastatin, n = 10 001 with CAD) showed
that intensive treatment with atorvastatin in
patients with stable coronary disease significantly
reduces subsequent hospitalizations for CHF
compared with low-dose therapy (2.4% vs. 3.3%, 
P = 0.0116) [43]. Moreover, this benefit was most
pronounced in patients with a history of CHF 
(41% lower, P = 0.008), while in patients without
a history of CHF, hospitalization rates for CHF were
similar in the high- and low-dose atorvastatin
groups.
Contrary to the previously mentioned reports of
benefit with statin therapy, two large, prospective
randomized trials with robust clinical end points
present conflicting data. The CORONA trial [3]
assessed the effectiveness and safety of
rosuvastatin 10 mg versus placebo in addition to
optimal CHF treatment in prevalent symptomatic
CHF cases, with a history of myocardial infarction
and not previously treated with a statin. The study
reported no effect on all-cause mortality and
hospitalization over the median follow-up period of
32 months (HR 0.95; P = 0.31), though safety of the
statin was demonstrated. With regards to the
reasons why CORONA did not show the expected
benefits, one possibility is the study population
(CORONA included elderly subjects [mean age 73
years; 41% were older than 75 years] with severe
systolic CHF, and 61% of the CHF population was
New York Heart Association [NYHA] class III with
a mean ejection fraction of 31%). It is possible that
rosuvastatin was administered too late in the
natural course of CHF to show a benefit. Another
explanation is that patients in the CORONA study
were receiving almost optimal background
treatment for CHF (most patients were on a renin-
angiotensin-aldosterone system [RAAS] blocker
[91%], a loop or thiazide diuretic [89%], a beta-
blocker [75%], and antiplatelet or anticoagulant
therapy [90%]). Therefore, it might be that the
CORONA population was “too well treated” to
achieve an additional benefit from statins. The
GISSI-HF trial [4] enrolled patients aged 18 years or
older with symptomatic CHF of ischaemic and non-
ischaemic cause, randomly assigned them to
rosuvastatin 10 mg daily or placebo, and followed
them up for a median of 3.9 years. No effect was
seen in all-cause mortality or combined mortality
and hospital admissions (HR 1.0 and 1.1,
respectively). The GISSI-HF trial differed from the
CORONA trial in some aspects of the population
enrolled (lower proportion with ischaemic aetiology,
younger age, and less severe symptoms). However,
patients in the GISSI-HF study were also receiving
optimal background treatment for CHF and might
be “too well treated” to achieve an additional
benefit from statins. Moreover, it remains possible
that benefits of statins may be offset by a negative
impact of cholesterol lowering in CHF patients, as
some evidence suggests that low serum total
cholesterol is associated with a marked increase in
mortality in advanced CHF.
Although there is overwhelming evidence that
statins are equally effective for primary and
secondary prevention of cardiovascular disease,
statins may differ in their properties in patients with
CHF and most of the studies with favourable
outcomes used drugs other than rosuvastatin.
Likewise, the present meta-analysis found that
atorvastatin could significantly decrease risks of all-
cause mortality, cardiovascular mortality, sudden
cardiac death and hospitalization for worsening
symptoms as compared to placebo in patients with
CHF. One of the differences between atorvastatin
and rosuvastatin is lipophilicity. Atorvastatin is more
lipophilic than rosuvastatin and may penetrate the
cell membrane more effectively, which could
provide a theoretical advantage [45]. Moreover,
lipophilic statins may be superior to hydrophilic
statins in preventing cardiovascular events because
of their potent pleiotropic effects such as the
inhibition of pro-inflammatory cytokine production
or matrix metalloproteinase expression [46, 47].
These results suggested that different statins may
have inconsistent benefits regarding important
clinical consequences of CHF. Thus, the fact that
a unique statin agent (rosuvastatin) was used in
CORONA and GISSI-HF trials might be one of the
causes of their negative results, which could not be
automatically extrapolated to other statins.
Our results suffer from those limitations which
are inherent to all meta-analytic techniques,
including particularly heterogeneity in patient
populations, different study drug regimens, and
variable endpoint definitions and follow-up periods
across studies. In particular, in this analysis we used
aggregate data as reported or calculated in
published articles, rather than data of individual
patients. Furthermore, although there was no
statistical heterogeneity in our analysis, the number
of patients is very small overall and also in each
trial, and the number of events is very small. Given
the mean small sample size of the studies included
Effect of atorvastatin in CHF
Arch Med Sci 6, December / 2010 871in our study, our findings should be interpreted with
caution. Further large, well-conducted randomized
trials are needed to confirm the benefits of
atorvastatin or other statins for CHF relative to
placebo or rosuvastatin.
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